Bevacizumab in advanced NSCLC: chemotherapy partners and duration of use.
about
Comparison of bevacizumab plus chemotherapy with chemotherapy alone in advanced non-small-lung cancer patientsMetabolic alterations underlying Bevacizumab therapy in glioblastoma cells.Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes.Incidence and risk of thromboembolism associated with bevacizumab in patients with non-small cell lung carcinoma
P2860
Bevacizumab in advanced NSCLC: chemotherapy partners and duration of use.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Bevacizumab in advanced NSCLC: chemotherapy partners and duration of use.
@en
type
label
Bevacizumab in advanced NSCLC: chemotherapy partners and duration of use.
@en
prefLabel
Bevacizumab in advanced NSCLC: chemotherapy partners and duration of use.
@en
P2093
P2860
P1476
Bevacizumab in advanced NSCLC: chemotherapy partners and duration of use.
@en
P2093
Jyoti D Patel
Ryan D Gentzler
Sarah E Yentz
P2860
P2888
P304
P356
10.1007/S11864-013-0255-3
P577
2013-12-01T00:00:00Z
P6179
1042077591